CTI BioPharma Ratios and Metrics

Market cap in millions HKD. Fiscal year is January - December.

Millions HKD. Fiscal year is Jan - Dec.

Fiscal Year	Current	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	2016 - 2019
Period Ending	Jul '25 Jul 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020	2016 - 2019
Market Capitalization	122	98	98	138	140	174	Upgrade
Market Cap Growth	-	-	-28.99%	-1.43%	-19.54%	-	Upgrade
Enterprise Value	55	39	66	104	73	47	Upgrade
Last Close Price	0.06	0.05	0.05	0.07	0.07	0.09	Upgrade
PE Ratio	32.09	25.78	-	-	-	-	Upgrade
PS Ratio	1.33	1.07	0.38	0.49	0.79	2.55	Upgrade
PB Ratio	0.57	0.46	0.47	0.64	0.62	0.76	Upgrade
P/TBV Ratio	0.57	0.46	0.47	0.64	0.62	0.76	Upgrade
P/FCF Ratio	-	-	6.63	-	-	-	Upgrade
P/OCF Ratio	-	-	6.49	-	-	-	Upgrade
EV/Sales Ratio	0.60	0.43	0.25	0.37	0.41	0.69	Upgrade
EV/EBITDA Ratio	11.24	8.06	-	-	-	-	Upgrade
EV/EBIT Ratio	24.29	17.42	-	-	-	-	Upgrade
EV/FCF Ratio	-33.53	-	4.43	-	-	-	Upgrade
Debt / Equity Ratio	0.03	0.03	0.03	0.04	0.04	0.00	Upgrade
Debt / EBITDA Ratio	1.25	1.25	-	-	-	-	Upgrade
Debt / FCF Ratio	-	-	0.47	-	-	-	Upgrade
Asset Turnover	0.35	0.35	0.98	1.05	0.67	0.29	Upgrade
Quick Ratio	5.74	5.74	4.66	4.77	6.59	6.53	Upgrade
Current Ratio	5.74	5.74	5.06	5.21	6.63	7.09	Upgrade
Return on Equity (ROE)	1.80%	1.80%	-3.74%	-3.05%	-2.13%	-10.44%	Upgrade
Return on Assets (ROA)	0.54%	0.54%	-1.49%	-1.62%	-1.27%	-3.14%	Upgrade
Return on Capital (ROIC)	0.65%	0.65%	-1.78%	-1.89%	-1.45%	-3.87%	Upgrade
Return on Capital Employed (ROCE)	1.00%	1.00%	-	-	-	-	Upgrade
Earnings Yield	3.12%	3.88%	-8.13%	-4.88%	-3.45%	-11.28%	Upgrade
FCF Yield	-1.34%	-1.67%	15.10%	-4.11%	-47.28%	-29.37%	Upgrade
Buyback Yield / Dilution	-	-	-	-	-3.10%	-29.33%	Upgrade

Source: S&P Global Market Intelligence. Standard template. Financial Sources.